Cite
HARVARD Citation
Tourneau, C. et al. (n.d.). 793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity. Journal for immunotherapy of cancer. p. A474. [Online].